The discourse of architectural bioconstruction: popularization and legitimation in professional journals

This study analyzes various professional journals form the field of architecture and construction in order to examine how the discourse of the bioconstruction is introduced and legitimatized. In this textual genre, the construction of the professionalization of this emerging discipline is carried out through various discursive strategies such as didacticity, metaphorization and ideological legitimization.En este trabajo se analizan diversas revistas profesionales del campo de la arquitectura y la construcción con el fin de estudiar de qué manera se introduce y se legitima el discurso de la bioconstrucción. El proceso de la profesionalización de esta disciplina emergente se lleva a cabo mediante diversas estrategias discursivas como la didacticidad, la metaforización y la legitimación ideológica

Contrastive analysis of computer terminology in Catalan and in Spanish

[EN] En aquest article duem a cap un estudi descriptiu i contrastiu de la terminologia de l¿àmbit de la informàtica en les llengües catalana i espanyola. S¿hi parteix dels termes anglesos corresponents atès que aquest treball naix amb l¿objectiu didàctic de millorar les competències terminològiques multilingües de l¿alumnat universitari de l¿enginyeria informàtica. Ordenem els vocabularis d¿informàtica de les tres llengües a partir dels recursos de formació de termes més freqüents, amb la idea de facilitar-ne l¿aprenentatge per part dels estudiants.[EN] In this paper we present a descriptive and contrastive study of computer terminology in the Catalan and Spanish languages. The study is based on the respective English terms since it has the didactic purpose of improving the multilingual terminological skills of university computer engineering students. We arrange the computer vocabularies of the three languages on the basis of the most common term formation resources with the aim to facilitate their learning for students.Montesinos López, AI. (2018). Anàlisi contrastiva de la terminologia informàtica en català i en espanyol. Terminàlia. (18):37-44. https://doi.org/10.2436/20.2503.01.12537441

Electronic communication and orality discourse

[EN] La comunicació electrònica és un reflex de la societat actual, de les seues tendències i dels seus valors culturals. En aquest sentit, hi ha una alta valoració cap a la informalitat i es produiexen fenòmens canviants dels paràmetres establerts quant a la privacitat, l¿afectivitat, etc. l¿intercanvi comunicatiu digital. Així mateix, s¿estableix un canvi predominant cap a formes oralitzants en l¿escriptura i les pràctiques socials electròniques contribueixen als canvis fonamentals en la distinció entre les formes parlades i escrites de la llengua. Actualment, es generen processos d¿informalització o conversalització i tecnologització del discurs i en les pràctiques discursives es detecten mescles d¿estils formals i informals, marcadors de familiaritat. En aquest sentit, la comunicació electrònica es diferencia d¿altres formes comunicatives per la presència de determinades expressions abreujades, representacions emocionals, per una ortografia no estàndard i la disminució de la densitat informativa, entre altres trets.[EN] Electronic communication is a reflection of today¿s societ and, its tendencies and cultural values. In this sense, a premium is placed on informality, and phenomena are at work within the digital exchange of information that are changing longestablished parameters affecting privacy, expressions of emotion, etc. Meanwhile, there has been a pronounced shift toward forms of writing that are more similar to oral discourse. Electronic communication has contributed to fundamental changes in the distinctions between spoken and written language. There is currently a process of ever-greater informality and conversationality. Contempoarary discursive styles mix formal and informal styles and display a number of familiarity markers are detected. In this sense, electronic communication differs from other communicative forms due to the presence of certain expressions, abbreviations, emotional representations, nonstandard spellings and the reduction of information density, among other features.Montesinos López, AI. (2018). La comunicació electrónica i l'oralització discursiva. Cultura Lenguaje y Representación. (20):269-284. https://doi.org/10.6035/CLR.2018.20S2692842

Anàlisi sociolingüística de l'evolució de la llengua catalana a la Universitat Politècnica de València (UPV)

[EN] The situation of the Catalan language in higher education is a significant indicator of its linguistic use in the academic world as well as the students` linguistic formation and the graduate students` specific communication skills in Catalan. Regardless of what is pointed out in the Law of use of the Valencian language and the European Charter for Regional or Minority Languages (point 879), the Universitat Politècnica de València¿s linguistic policy regarding the teaching in Valencian and the teaching of Valencian for specific purposes has suffered a drastic reduction compared to previous years; thus it can be asserted that such a language policy is against what is established normatively by a higher stage of proceeding which has outstanding consequences concerning the standardisation of Valencian in higher educationMontesinos López, AI.; Bracho Lapiedra, L. (2019). Anàlisi sociolingüística de l'evolució de la llengua catalana a la Universitat Politècnica de València (UPV). Zeitschrift für Katalanistik. (32):199-222. http://hdl.handle.net/10251/157494S1992223

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida.This study received funding from SCYNEXIS. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of the article, or the decision to submit it for publication. CM-A is a recipient of a grant from Fundació n ONCE (Oportunidad al Talento). EE, AG, NJ, CM-A, and GQ have received grant support from Consejerı́a de Educación, Universidades e Investigación del Gobierno Vasco (GIC15 IT-990-16), Fondo de Investigación Sanitaria del Gobierno de España (FIS PI11/00203), and UPV/EHU (UFI 11/25). All authors declare no other competing interests

Discourse Analysis and Terminology in Languages for Specific Purposes

Aquest importantíssim recull conté estudis i reflexions sobre temes rellevants en la recerca sobre LSP: anglès mèdic, el llenguatge de la publicitat i periodístic, telecomunicacions i terminologia informàtica, llenguatge comercial i jurídic... Malgrat que gran part dels treballs aplegats es refereixen a l'anglès, també hi ha que tracten l'alemany, francès i altres llengües. Conté textos en anglès, francés, portuguès i castellà

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome–negative (Ph−) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance remains unclear. The aim of the ALL-HR-11 trial was to evaluate the outcomes of HR Ph− adult ALL patients following chemotherapy or allo-HSCT administered based on end-induction and consolidation MRD levels. Patients aged 15 to 60 years with HR-ALL in complete response (CR) and MRD levels (centrally assessed by 8-color flow cytometry) <0.1% after induction and <0.01% after early consolidation were assigned to receive delayed consolidation and maintenance therapy up to 2 years in CR. The remaining patients were allocated to allo-HSCT. CR was attained in 315/348 patients (91%), with MRD <0.1% after induction in 220/289 patients (76%). By intention-to-treat, 218 patients were assigned to chemotherapy and 106 to allo-HSCT. The 5-year (±95% confidence interval) cumulative incidence of relapse (CIR), overall survival (OS), and event-free survival probabilities for the whole series were 43% ± 7%, 49% ± 7%, and 40% ± 6%, respectively, with CIR and OS rates of 45% ± 8% and 59% ± 9% for patients assigned to chemotherapy and of 40% ± 12% and 38% ± 11% for those assigned to allo-HSCT, respectively. Our results show that avoiding allo-HSCT does not hamper the outcomes of HR Ph− adult ALL patients up to 60 years with adequate MRD response after induction and consolidation. Better postremission alternative therapies are especially needed for patients with poor MRD clearance

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Ahora / Ara

La cinquena edició del microrelatari per l’eradicació de la violència contra les dones de l’Institut Universitari d’Estudis Feministes i de Gènere «Purificación Escribano» de la Universitat Jaume I vol ser una declaració d’esperança. Aquest és el moment en el qual les dones (i els homes) hem de fer un pas endavant i eliminar la violència sistèmica contra les dones. Ara és el moment de denunciar el masclisme i els micromasclismes començant a construir una societat més igualitària. Cadascun dels relats del llibre és una denúncia i una declaració que ens encamina cap a un món millor

Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.

Background: Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods: Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks. Results: Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch. Conclusions: One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch